These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6362258)

  • 21. Can the routine treatment of Graves' orbitopathy be efficiently supplemented by the administration of Venalot?
    Frank K; Ding G; Raue F; Ziegler R
    Dev Ophthalmol; 1989; 20():127-9. PubMed ID: 2687048
    [No Abstract]   [Full Text] [Related]  

  • 22. [Venoruton in chronic venous insufficiency].
    Golden GJ
    Ugeskr Laeger; 1993 Jan; 155(3):182-3. PubMed ID: 8421882
    [No Abstract]   [Full Text] [Related]  

  • 23. [Modifications induced by long-term treatment with high doses of 0-(beta-hydroxyethyl)-rutoside in chronic venous insufficiency].
    Barbarino C; Pezzangora V
    Vasa Suppl; 1989; 27():120. PubMed ID: 2623482
    [No Abstract]   [Full Text] [Related]  

  • 24. [Antiphlogistics for sprained ankles. A consecutive, prospective double-blind study].
    Helmig O; Schrøder HM; Wethelund JO
    Ugeskr Laeger; 1987 Jul; 149(29):1954-6. PubMed ID: 3433415
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical improvement in chronic venous insufficiency signs and symptoms with Venoruton® (HR): an 8-month, open-registry, cost-efficacy study.
    Cesarone MR; Belcaro G; Ippolito E; Pellegrini L; Ledda A; Luzzi R; Ricci A; Dugall M; Bavera P; Hosoi M; Stuard S; Corsi M
    Panminerva Med; 2010 Jun; 52(2 Suppl 1):43-8. PubMed ID: 20657534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of O-(beta-hydroxyethyl)-rutosides in the treatment of venous leg ulcers].
    Stegmann W; Hubner K; Deichmann B; Muller B
    Phlebologie; 1987; 40(1):149-56. PubMed ID: 3554278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of sudden deafness of vascular etiology with venoruton].
    Madej S
    Otolaryngol Pol; 1989; 43(3):214-7. PubMed ID: 2695884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions.
    Perrin M; Ramelet AA
    Eur J Vasc Endovasc Surg; 2011 Jan; 41(1):117-25. PubMed ID: 21126890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paroven: not much effect in trials.
    Drug Ther Bull; 1992 Jan; 30(2):7-8. PubMed ID: 1555498
    [No Abstract]   [Full Text] [Related]  

  • 30. [Hormonal contraceptives, peripheral venous insufficiency and the use of a phlebodynamic agent].
    Cervantes A; Gorodovsky J; Peña A; Campos J
    Ginecol Obstet Mex; 1976 Aug; 40(238):113-6. PubMed ID: 786800
    [No Abstract]   [Full Text] [Related]  

  • 31. [Prevention of cystoid macular edema with O-beta-hydroxyethyl-rutoside (Venoruton) in a double-blind study].
    Artaria LG
    Klin Monbl Augenheilkd; 1982 Jun; 180(6):568-70. PubMed ID: 6752553
    [No Abstract]   [Full Text] [Related]  

  • 32. An open-label, randomised multicentre study comparing the efficacy and safety of CYCLO 3 FORT versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency.
    Beltramino R; Penenory A; Buceta AM
    Int Angiol; 1999 Dec; 18(4):337-42. PubMed ID: 10811525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of benzopyrones in posttraumatic inflammations/Clinical double blind study in the postoperative treatment of episiotomy (author's transl)].
    Pethö A
    Arzneimittelforschung; 1981; 31(8):1303-7. PubMed ID: 7028045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New aspects in the pathogenesis of chronic venous insufficiency and the place of localized action of Venoruton].
    Bekers S; Zilstra I
    Akush Ginekol (Sofiia); 2002; 41 Suppl 2():28-32. PubMed ID: 19705689
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinico-statistical study on the activity of a phlebo-active drug Fleboplex in obstetrical and gynecologic pathology].
    Ricci MG
    Minerva Ginecol; 1974 Nov; 26(11):641-6. PubMed ID: 4444806
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of O-(beta-hydroxyethyl)-rutosides at high dosage in counteracting the unwanted activity of oral contraceptives on venous function.
    Cappelli R; Pecchi S; Oberhauser V; Forconi S; Di Perri T
    Int J Clin Pharmacol Res; 1987; 7(4):291-9. PubMed ID: 3596872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and Daflon.
    Frick RW
    Angiology; 2000 Mar; 51(3):197-205. PubMed ID: 10744007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative investigations on the treatment of the varicose syndrome with 4-methyl-6,7-(bis-beta-diethyl-aminoethoxy)-coumarine hydrochloride (oxamarine), with the disodium salt of disulphuric ester of 4-methyl-aesculetol and with tri-hydroxy-ethylrutoside (troxerutin).
    Frandoli G; Turazza G; Spreafico PL
    Panminerva Med; 1972 Sep; 14(9):290-5. PubMed ID: 4618898
    [No Abstract]   [Full Text] [Related]  

  • 39. An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency.
    Beltramino R; Penenory A; Buceta AM
    Angiology; 2000 Jul; 51(7):535-44. PubMed ID: 10917578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Venoruton in the therapy of central retinal vein occlusion.
    Zygulska-Mach H; Kostka-Trabka E; Kielar J; Grodzinska L; Dieron K; Kedzior A
    Ther Hung; 1985; 33(2):79-82. PubMed ID: 3842005
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.